Thyroid tumors: As noted, this is primarily based on rodent findings
This reluctance is likely to be at least partially attributable to the fact that, until recently, all GLP-1RAs were available as subcutaneous (s.c.) injections, given twice daily (exenatide [13]), once daily (lixisenatide [14] and liraglutide [15]), or once weekly (semaglutide [16], dulaglutide [17], and exenatide extended release [18]), a route that may be less preferable to some patients compared with oral administration [1, 19]
They may or may not include updated dosing instructions
For Houston residents, the Trump deal not only promises lower fixed-cost options through direct-purchase tiers but also enhances negotiating power for local insurers and pharmacies, potentially reducing typical cash retail variability